시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 비교리스트
세계의 야뇨증 시장 보고서(2025년)
Nocturia Global Market Report 2025
상품코드 : 1720841
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,183,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 8,938,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 11,692,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

야뇨증 시장 규모는 향후 수년간 강력한 성장이 예상될 예정입니다. 높은 수분 섭취, 수면장애나 신장의 건강과의 관련성에 대한 의식의 고조, 고령화 인구의 확대 등에 기인한다고 생각됩니다.

심혈관 질환의 유병률 증가는 야뇨증 시장의 확대를 촉진할 것으로 예상되고 있습니다. 알코올 섭취, 비만, 고혈압, 고콜레스테롤, 당뇨병, 유전적 소인 등 여러 요인이 심혈관 질환의 발생률 증가의 원인이 되고 있습니다. 고령화와 건강에 해로운 라이프스타일로 인해 심혈관질환은 세계적으로 증가하고 있으며, 효과적인 야뇨증 관리의 필요성은 확대됩니다. 예를 들어, 2024년 5월, 미국에 본사를 둔 정부 기관인 질병통제예방센터는 2022년 미국에서 심장병으로 인한 사망자가 702,880명으로 전체 사망자의 20%를 차지한다고 보고했습니다. 매년, 약 80만 5,000명이 심장 발작을 일으켜, 60만 5,000명이 첫 발병, 20만명이 기왕력이 있는 사람에게 발병하고 있습니다. 결과적으로 심혈관 질환의 유병률이 증가함에 따라 야뇨증 시장의 성장이 촉진되고 있습니다.

야뇨증 시장의 주요 기업은 환자의 편의성과 컴플라이언스를 향상시키기 위해 구강내 붕괴정과 같은 혁신적인 치료법의 개발에 주력하고 있습니다. 예를 들어, 2024년 7월, 몰타에 본사를 두는 제약회사 아달보 리미티드는 중추성 두개 당뇨병성 불정오소 등의 과잉 수분 손실을 일으키는 질병의 치료로서 데스모프레신 ODT를 유럽에서 출시했습니다. 병성 부정 불소, 과도한 갈증 및 배뇨, 야뇨증 관리에 도움이 됩니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 전략

제36장 부록

SHW
영문 목차

영문목차

Nocturia is a medical condition characterized by the need to wake up at night one or more times to urinate. It is classified as a lower urinary tract symptom (LUTS) and can stem from various underlying causes, such as excessive fluid intake before bedtime, overactive bladder, urinary tract infections, diabetes, or prostate enlargement in men. Nocturia can significantly affect sleep quality and overall health, leading to fatigue and reduced daytime productivity.

The primary drugs used for nocturia treatment include anticholinergic drugs, desmopressin, antibiotics, antispasmodics, and other medications. Anticholinergic drugs work by blocking acetylcholine to reduce involuntary bladder contractions, helping to manage overactive bladder and nocturia. These medications are indicated for conditions such as mixed nocturia, low nocturnal bladder capacity, nocturnal polyuria, and global polyuria. Nocturia can be caused by factors such as urological infections, bladder tumors, diuretic medications, alcohol or caffeine consumption, liver infections, diabetes, and pregnancy. These treatments are utilized by various end users, including hospitals, home care settings, and clinics.

The nocturia market research report is one of a series of new reports from The Business Research Company that provides nocturia market statistics, including the nocturia industry global market size, regional shares, competitors with the nocturia market share, detailed nocturia market segments, market trends, and opportunities, and any further data you may need to thrive in the nocturia industry. This nocturia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The nocturia market size has grown strongly in recent years. It will grow from $2.87 billion in 2024 to $3.11 billion in 2025 at a compound annual growth rate (CAGR) of 8.4%. The growth during the historic period can be attributed to the increasing prevalence of cardiovascular diseases, a rising incidence of insomnia, an aging population, greater awareness of nocturia and related conditions, and a rise in comorbidities.

The nocturia market size is expected to see strong growth in the next few years. It will grow to $4.23 billion in 2029 at a compound annual growth rate (CAGR) of 8.0%. The growth during the forecast period can be attributed to the increasing prevalence of bladder obstruction disorders and urinary tract inflammation, a rising incidence of nocturia due to various risk factors, high fluid intake contributing to nocturia, growing awareness of its connection to sleep disorders and kidney health, and the expanding aging population. Key trends in the forecast period include advancements in diagnostics, the development of new drugs, increased research and investment in nocturia treatments, progress in both surgical and non-surgical treatment options, and the adoption of personalized medicine.

The increasing prevalence of cardiovascular diseases is expected to drive the expansion of the nocturia market. Cardiovascular diseases (CVDs) encompass a range of disorders affecting the heart and blood vessels, including heart disease, stroke, and hypertension. Several factors contribute to the growing incidence of cardiovascular diseases, such as aging populations, sedentary lifestyles, unhealthy diets, smoking, excessive alcohol consumption, obesity, high blood pressure, high cholesterol, diabetes, and genetic predisposition. Nocturia is a common symptom among patients with cardiovascular diseases, leading to increased demand for diagnostic and treatment solutions. As cardiovascular conditions continue to rise globally due to aging and unhealthy lifestyles, the need for effective nocturia management will expand. For example, in May 2024, the Centers for Disease Control and Prevention, a US-based government agency, reported that heart disease was responsible for 702,880 deaths in the United States in 2022, accounting for 20% of all fatalities. Each year, approximately 805,000 individuals suffer a heart attack, with 605,000 being first-time cases and 200,000 occurring in those with a prior history. Consequently, the rising prevalence of cardiovascular diseases is fueling the growth of the nocturia market.

Leading companies in the nocturia market are focusing on developing innovative treatments, such as orally disintegrating tablets, to improve patient convenience and compliance. Orally disintegrating tablets (ODTs) are solid dosage forms that dissolve rapidly in the mouth without requiring water, making them particularly beneficial for patients who have difficulty swallowing. For instance, in July 2024, Adalvo Limited, a Malta-based pharmaceutical company, launched Desmopressin ODT in Europe to treat conditions that cause excessive fluid loss, such as central cranial diabetes insipidus. This synthetic vasopressin tablet helps manage diabetes insipidus, excessive thirst and urination, and bedwetting by mimicking the natural hormone and reducing water excretion in urine. Additionally, it is used to treat mild to moderate hemophilia A and von Willebrand disease by promoting the release of blood clotting factors.

In March 2022, Acerus Pharmaceuticals Corporation, a Canada-based biopharmaceutical company, acquired Serenity Pharmaceuticals LLC for an undisclosed amount. This acquisition granted Acerus Pharmaceuticals global rights to Noctiva, strengthening its portfolio in urology and men's health. The deal positions the company for accelerated growth and improved long-term performance. Serenity Pharmaceuticals LLC, a US-based pharmaceutical company, specializes in developing therapies for voiding disorders and urinary health conditions, including nocturia.

Major players in the nocturia market are Pfizer Inc, Merck & Co. Inc, AbbVie Inc, Sanofi S.A, GlaxoSmithKline plc, Viatris Inc, Boehringer Ingelheim International GmbH, Otsuka Pharmaceutical Co. Ltd, Astellas Pharma Inc, Eisai Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd, Ferring Pharmaceuticals A/S, Avadel Pharmaceuticals plc, UroGen Pharma Ltd, Sanwa Kagaku Co. Ltd., Urovant Sciences Inc, Serenity Pharmaceuticals LLC, Vantia Therapeutics Inc, AA Pharma Inc, Wellesley Pharmaceuticals Inc.

North America was the largest region in the nocturia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in nocturia report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the nocturia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The nocturia market consists of revenues earned by entities by providing services such as diagnostic services, pharmacological treatment services, behavioral therapy and lifestyle modification services and telemedicine and remote consultation services. The market value includes the value of related goods sold by the service provider or included within the service offering. The nocturia market also includes sales of bladder control devices, alpha-blockers, diuretics, and tricyclic antidepressants. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Nocturia Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on nocturia market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for nocturia ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The nocturia market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Nocturia Market Characteristics

3. Nocturia Market Trends And Strategies

4. Nocturia Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Nocturia Growth Analysis And Strategic Analysis Framework

6. Nocturia Market Segmentation

7. Nocturia Market Regional And Country Analysis

8. Asia-Pacific Nocturia Market

9. China Nocturia Market

10. India Nocturia Market

11. Japan Nocturia Market

12. Australia Nocturia Market

13. Indonesia Nocturia Market

14. South Korea Nocturia Market

15. Western Europe Nocturia Market

16. UK Nocturia Market

17. Germany Nocturia Market

18. France Nocturia Market

19. Italy Nocturia Market

20. Spain Nocturia Market

21. Eastern Europe Nocturia Market

22. Russia Nocturia Market

23. North America Nocturia Market

24. USA Nocturia Market

25. Canada Nocturia Market

26. South America Nocturia Market

27. Brazil Nocturia Market

28. Middle East Nocturia Market

29. Africa Nocturia Market

30. Nocturia Market Competitive Landscape And Company Profiles

31. Nocturia Market Other Major And Innovative Companies

32. Global Nocturia Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Nocturia Market

34. Recent Developments In The Nocturia Market

35. Nocturia Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기